Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers
David G. Soergel(Novartis (Switzerland)), Lynn R. Webster(Adherent Technologies (United States)), Ruth Ann Subach, Michael W. Lark, Brian M. Sadler(The University of Texas at Austin), Franck Skobieranda(Ionis Pharmaceuticals (United States)), Nancy Burnham(Statistical Research (United States)), Ian E. James, Jonathan D. Violin
Cited by 264
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304